Aktis Oncology rallies $72m Series A
Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing.
Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination